February 2, 2010 9:20 AM
- Text
'Dr. Nobody' Says 74% of Medical Schools Don't Ban Ghostwriting
(MoneyWatch) Seventy-four percent of top medical schools have no policy prohibiting ghostwriting, according to a new study in Public Library of Science Medicine. The study was conducted by Dr. Jonathan Leo (top) and Jeffrey R. Lacasse, whom regular readers will remember were responsible for twisting JAMA into knots when they pointed out -- correctly -- that one of its authors had failed to disclose a conflict of interest with Forest Labs (FRX). A JAMA editor famously called Leo "a nobody and a nothing" for doing that.
The pair point out that only 26 percent of schools have a policy that prohibits ghostwriting. Among the companies that have been exposed as providing ghostwriters for medical and academic authors recently are Forest, AstraZeneca (AZN), Merck (MRK), Wyeth and GlaxoSmithKline (GSK).
The pair (from Arizona State University's School of Social Work in Phoenix and Lincoln Memorial University-DeBusk College of Osteopathic Medicine in Harrogate, Tenn., respectively) conclude that ghostwriting is a danger to public health:
The pair point out that only 26 percent of schools have a policy that prohibits ghostwriting. Among the companies that have been exposed as providing ghostwriters for medical and academic authors recently are Forest, AstraZeneca (AZN), Merck (MRK), Wyeth and GlaxoSmithKline (GSK).The pair (from Arizona State University's School of Social Work in Phoenix and Lincoln Memorial University-DeBusk College of Osteopathic Medicine in Harrogate, Tenn., respectively) conclude that ghostwriting is a danger to public health:
We are not aware of any other academic fields where it is acceptable for professors to allow themselves to be listed as authors on research papers they did not write, or to purposefully conceal the contributions of industry coauthors in order to mislead readers.
They urge medical school deans to institute an immediate ban on ghostwriting.Pharmaceutical companies have used ghostwriting to market sertraline [17], olanzapine [18], gabapentin [19], estrogen replacement therapy [20], rofecoxib [2], paroxetine [4],[21], methylphenidate [22], milnaciprin [23], venlafaxine [24], and dexfenfluramine [25]. Ghostwriting is now known to be a major industry [26].
- Related:
- Forest's Lexapro Ghostwriting Budget Was $100K; Emory on the Payroll
- Inside GSK's CASSPER Ghostwriting Program
- "CASSPER" Was GSK's Friendly Ghostwriting Program on Paxil
- Docs Say Merck Placed Their Names on Ghostwritten Vioxx Articles
- Elsevier Accused Again in Ghostwriting Scandal - This Time in Wyeth Prempro/Premarin Cases
- Wyeth's Troubles: Ghostwriting to Be Revealed; Centrum Sales Weak
- AstraZeneca's "Smoke and Mirrors" Man Has New Job in Medical Writing
- AZ Seroquel Trial: Was It "Ghostwriting" or "Professional" Writing?
Latest Now in MoneyWatch
- Many small business owners favor "Buffett rule"
- Jeremy Grantham's investing strategies for 2012
- iPhone hurts Sprint profits
- Most companies are complacent and narcissistic
- Look to weaknesses to find your leadership strengths
- McDonald's key revenue figure up 6.7 pct. in Jan.
- Home foreclosures decline, but completions rise
- "Person to Person" to feature Warren Buffett
- Time Warner beats earnings expectations
- 18 tax credits and deductions to take this year
- Sprint posts deeper loss on iPhone costs
- Is this a stock-picker's year?
- Urban farming on the rise nationwide
- Consumer debt skyrocketed in 4th quarter
- Find your next job with help from Glassdoor
- Should I rat out my boss?
- How real leaders come from behind and win
Latest CBS News Headlines
on Facebook Most Discussed Stories
on CBS News
- Head of Eurogroup: eurozone finance ministers to meet Thursday to discuss Greece bailout
- French TV sued over skit linking Nadal to doping
- Netherlands prepares for 125-mile skating race
- United Tech downplays issuing stock for Goodrich
on Facebook Most Discussed Stories
on CBS News







